BARNETTE K GARY purchased $5K of VERU

BARNETTE K GARY (Chief Scientific Officer) purchased 1,800 shares of VERU INC. (VERU) at $2.69 on 2026-08-13.

Original reporting
SEC EDGAR · BARNETTE K GARY
Published Aug 17, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VERU
Neutral
low confidence
Mentioned
$VERU
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VERUNeutralLow
01

Why it matters

The only new fact is the insider’s open-market purchase size, price, and post-transaction holdings; it does not include guidance, trial results, or corporate actions.

02

Market read

Traders may note insider buying as a minor sentiment input, but there is no fundamental update to reprice the stock materially.

03

What to watch

The text notes no pre-arranged 10b5-1 plan, but it still does not reveal intent, timing constraints, or whether the purchase is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for VERU.

Company-level read

Ticker impact

$VERUNeutralLow confidence
Context

SEC Form 4 shows Chief Scientific Officer Barnette K. Gary bought 1,800 VERU shares at $2.6899 on 2026-08-13.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and small versus broader company fundamentals.

Evidence & confidence

The filing is a routine insider transaction with no new operational, financial, or regulatory information disclosed in the text.

Market effects

No sector-level implications are provided beyond a single insider trade.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary, tax-related, or part of routine compensation activity, so the signal may be weak.

Key entities

  • VERU

    Issuer of the Form 4 insider transaction disclosed in the article.

  • BARNETTE K GARY

    Chief Scientific Officer at VERU who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$VERUMedAI 8/10

Veru executive to present obesity drug data at industry conference

Veru Inc. (VERU) will present obesity drug data at ObesityWeek 2026. Dr. Gary Barnette will discuss physical function in older patients using a GLP-1 receptor agonist from the QUALITY study. The company's Phase 2b PLATEAU trial has enrolled 239 patients, exceeding targets. Interim results are expected in Q1 2027, with final data in Q4 2027, according to the company.

$VERUMed

Why is Veru stock gaining today?

Veru Inc. (VERU) shares rose 1.8% after Oppenheimer reiterated its Outperform rating and $24 price target, citing confidence in enobosarm's Phase 2b trial results. The trial, fully enrolled with 239 patients, aims to show lean body mass preservation and fat loss benefits. Veru holds a U.S. patent for the enobosarm-semaglutide combination until 2044. The stock traded at $2.23, below its 52-week high of $7.33 but above its low of $2.05.

$VERUHighAI 8/10

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™)…

VERU INC. (VERU) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib